

Supplementary Table 2. Attainment of Individual MDA Components at Week 144 in MDA Achievers by Initial Randomized Treatment

MDA component	MDA Achievers Meeting Criterion, n (%)		Response difference (95% CI)
	Adalimumab (n=38)	Placebo (n=47)	
TJC ≤1	19 (50.0)	18 (38.3)	11.7 (−9.4 to 32.8)
SJC ≤1	21 (55.3)	22 (46.8)	8.5 (−12.8 to 29.8)
PASI ≤1	20 (52.6)	27 (57.5)	−4.8 (−26.1 to 16.4)
Patient pain ≤15	23 (60.5)	18 (38.3)	22.2 (1.38 to 43.1)*
PtGA ≤20	26 (68.4)	26 (55.3)	13.1 (−7.4 to 33.6)
HAQ-DI ≤0.5	22 (57.9)	24 (51.1)	6.8 (−14.4 to 28.1)
Tender enthesal points ≤1	36 (94.7)	42 (89.4)	5.4 (−5.94 to 16.7)

HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PtGA, Patient Global Assessment of disease activity; SJC, swollen joint count of 76 joints; TJC, tender joint count of 78 joints.

* $P < 0.05$.